| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research, and the Sloan-Kettering Division Graduate School of Medical Sciences, Cornell University, Medical College, New York, New York
Pyruvaldehyde bis(thiosemicarbazone) (PTS) was tested alone and in combination with dietary copper sulfate on 10 tumor systems. Potentiation of the cancerostatic activity of PTS by copper sulfate occurred in 8 of the tumor systems: Sarcoma 180, Taper liver tumor (solid and ascites), Carcinoma 1025, Sarcoma T241, Ridgway osteogenic sarcoma, Mecca lymphosarcoma, and Walker Rat Carcinosarcoma 256 (W256) as well as in the established 7-day-old W256 and 4-day-old Taper liver tumor (ascites). Copper ions appeared essential for activity of PTS in the treatment of the solid Taper liver tumor. In W256, calcium and zinc, in addition to copper, were able to enhance the antitumor activity of subinhibitory doses of the drug.
1 This study was supported by Contract No. SA-43-ph-2445 with The Cancer Chemotherapy National Service Center, National Cancer Institute, NIH, and in part by NCI Grant CA 08748.
Received 4/19/66. Accepted 1/ 9/67.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |